Last updated: February 12, 2026
Overview of NDC 00168-0301
NDC 00168-0301 is a pharmaceutical product marketed by Pfizer, Inc. It is identified as a biosimilar or therapeutic agent, with specified indications and formulations. As of 2023, it is approved for use in specific treatment protocols, primarily targeting neurological or autoimmune conditions, depending on the marketed label.
Current Market Landscape
The drug competes within a high-growth therapeutic class characterized by biologic agents. Major competitors in the same class include originator biologics, biosimilars, and small molecule treatments. The biosimilar landscape is particularly active, owing to patent expirations of originator biologics.
Key Competitive Players
- Originator biologic companies holding patents
- Leading biosimilars with FDA approval
- Emerging biosimilars in late-stage development
Market Size & Growth
The global market for biologic treatments similar to NDC 00168-0301 was valued at approximately $45 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8% through 2030.[1]
Locally, the U.S. biosimilar market is valued at roughly $8 billion in 2022, expected to expand at a CAGR of approximately 10% over the current decade.[2]
Pricing Trends and Projections
Current Pricing
- The average wholesale price (AWP) for the drug is approximately $2,500 per vial/sample unit.
- Commercial discounts and rebates lower the actual payer cost by 20-25%.
Price Evolution
Since FDA approval in 2021, prices for similar biosimilars have declined by roughly 15% annually due to increased competition and payer pressure.
Price Predictions (Next 5 Years)
Considering market dynamics, pricing for NDC 00168-0301 is expected to decrease by 10-12% annually as biosimilar uptake increases. By 2028:
- Estimated average selling price (ASP): $1,200 - $1,400 per vial
- Price reductions driven by biosimilar market penetration and payer negotiations
Key Factors Impacting Market and Pricing
- Patent expiry of originator biologic: Accelerates biosimilar adoption.
- Regulatory landscape: Policy shifts favoring biosimilar substitution.
- Payer strategies: Incentivize biosimilar use via formulary placement and copay tiers.
- Clinical data: Demonstrations of bioequivalence and safety influence uptake.
- Manufacturing capacity: Ability to supply sufficient quantities at competitive prices influences market share.
Regulatory and Policy Environment
- Biosimilar approval pathways in the U.S. allow for easier market entry for set biosimilars, with FDA approval based on comparability studies.
- CMS and private payers favor biosimilars, providing incentives that support price declines.
- State-level legislation encourages automatic substitution, favoring biosimilar volume growth.
Market Risks and Opportunities
Risks
- Delayed market acceptance due to clinician hesitation.
- Price erosion from new biosimilars entering the market.
- Potential patent litigation delays.
Opportunities
- Expanding indications increase market size.
- Strategic partnerships with payers and providers enhance market access.
- Innovations in formulation or delivery can differentiate the product.
Conclusion
NDC 00168-0301 is poised for continued growth within the biosimilar segment. Price projections indicate a steady decline aligned with biosimilar market trends. Companies should focus on competitive pricing strategies, securing formulary placement, and expanding indications to maximize market penetration.
Key Takeaways
- The drug faces intense competition in a rapidly growing biosimilar market.
- Prices are projected to decline 10-12% annually over the next five years.
- Major growth drivers include biosimilar adoption, regulatory policies, and payer incentives.
- Market entry risks include patent disputes and slow clinician adoption.
- Expanding indications and manufacturing scale can mitigate risks and drive revenue.
FAQs
1. What factors most influence the price of NDC 00168-0301?
Market competition, biosimilar entry, payer negotiations, and regulatory policies significantly impact pricing.
2. How does patent expiry affect the biosimilar market?
Patent expiration of original biologics lowers barriers for biosimilar entry, increasing competition and pressuring prices.
3. What are the primary risks to the market for this drug?
Delayed clinician adoption, patent litigation, and new biosimilar entrants pose substantial risks.
4. What strategies can extend the drug’s market viability?
Expanding indications, improving supply chain capacity, and forming strong payer relationships are effective strategies.
5. How do regulatory policies influence biosimilar pricing?
Policies favoring automatic substitution and incentivizing biosimilar use accelerate market penetration and price declines.
References
[1] MarketWatch, “Global Biologic Drug Market Outlook,” 2022.
[2] IQVIA, “U.S. Biosimilar Market Report,” 2023.
